Elanco Animal Health Inc

Latest Results (18.11.2025):

Elanco Animal Health Inc reported its third quarter 2025 financial results, with revenue reaching $1,137 million—a 10% increase year-over-year and 9% organic constant currency growth. Despite a reported net loss of $34 million, the company achieved an adjusted net income of $94 million and an adjusted EBITDA of $198 million at a 17.5% margin. Alongside these results, Elanco raised full-year revenue and innovation revenue targets for 2025 and improved its year-end net leverage ratio target, signaling strong performance and strategic progress.

Revenue and Growth

In Q3 2025, revenue increased to $1,137 million, reflecting a robust 10% year-over-year growth and demonstrating 9% organic constant currency expansion fueled by a diverse portfolio of innovative products.

Earnings and Margins

Elanco recorded a reported net loss of $34 million but delivered an adjusted net income of $94 million. The adjusted EBITDA reached $198 million, achieving a margin of 17.5%, underscoring operational strength despite challenging aspects.

Full Year 2025 Guidance

The company raised its full-year revenue guidance to between $4,645 million and $4,670 million, with expectations for accelerating organic constant currency revenue growth of 6% to 6.5%. Additionally, the full-year innovation revenue target was raised by $100 million to a range of $840 million to $880 million, complemented by improved net leverage ratio targets of 3.7x to 3.8x adjusted EBITDA.

Strategic Initiatives and Highlights

Elanco also highlighted key product successes, including milestone achievements for Credelio Quattro™ and Zenrelia™, along with strong sales growth for Experior® and AdTab™ in Q3. Strategic moves such as the refinancing of a $2.1 billion debt facility and the opening of a new global headquarters underscore the company’s commitment to enhancing its financial and operational profile.